Erdosteine

Erdosteine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth, inhalation
ATC code
Pharmacokinetic data
Protein binding65%
Metabolismliver
Elimination half-life1–3 hours
Identifiers
  • 2-[(2-Oxothiolan-3-yl)carbamoylmethylsulfanyl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.169.984 Edit this at Wikidata
Chemical and physical data
FormulaC8H11NO4S2
Molar mass249.30 g·mol−1
3D model (JSmol)
  • O=C1SCCC1NC(=O)CSCC(=O)O
  • InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12) checkY
  • Key:QGFORSXNKQLDNO-UHFFFAOYSA-N checkY
  (verify)

Erdosteine is a molecule with mucolytic activity. Structurally it is a thioether derivative with two thioether groups.[1] These two functional organosulfur groups contained in the molecule are released following first-pass metabolism with the conversion of erdosteine into its pharmacologically active metabolite Met-I.

The molecule has been discovered and developed in Italy by Edmond Pharma, today it is prescribed for chronic and acute respiratory disorders in more than 40 countries worldwide. The drug is sold under several commercial names (Esteclin, Erdomed, Erdos, Erdotin etc.), as hard capsules 300 mg, dispersible tablets 300 mg, granulates for oral suspension 225 mg and powder for oral suspension 175 mg/5ml.

  1. ^ Gobetti M, Pedrazzoli A, Bradamante S (January 1986). "DL-S-(2-[N-3-(2-oxo-tetrahydrothienyl)acetamido])-thioglycolic acid: a novel mucolytic agent of the class of homocysteine thiolactone derivatives". Il Farmaco; Edizione Scientifica. 41 (1): 69–79. PMID 3956722.